Theoretical basis and progress of fecal microbiota transplantation in metabolic associated fatty liver disease
10.3760/cma.j.cn115822-20230407-00053
- VernacularTitle:粪菌移植治疗代谢相关脂肪性肝病的理论基础和研究进展
- Author:
Lu REN
1
;
Xiaowei ZHANG
;
Na LIU
Author Information
1. 河北医科大学研究生院，石家庄 050017
- Keywords:
Metabolic associated fatty liver disease;
Dysbiosis;
Gut-liver axis;
Fecal microbiota transplantation;
Molecular mechanism
- From:
Chinese Journal of Clinical Nutrition
2023;31(4):244-250
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic associated fatty liver disease (MAFLD) is a cluster of chronic, progressive diseases with an increasing prevalence rate worldwide. MAFLD has become the leading cause of chronic liver disease around the world, for which approved therapy is currently lacking. In recent years, growing evidence has demonstrated the close link between gut microbiome dysbiosis and MAFLD. The generation of pro-inflammatory bacterial components and metabolites is susceptible to the changes in the abundance, diversity, and ratio of intestinal bacteria, which could accelerate the progress of MAFLD through the gut-liver axis. As a new therapeutic strategy, fecal microbiota transplantation (FMT) is the transplantation of flora from the intestines of healthy people into the gastrointestinal tract of patients, to directly correct intestinal flora disorders and alter bacterial metabolites. FMT has been widely used in the treatment of Clostridium difficile infections and inflammatory bowel disease. The role of FMT in the treatment of MAFLD has also been explored. However, studies about FMT in MAFLD are overall scarce and the mechanism of action and the therapeutic effect of FMT on MAFLD remains ambiguous. We summarized the existing evidence on the potential molecular mechanism and effectiveness related to FMT in MAFLD.
